- BMJ. 2004 Aug 21;329(7463):415-6 - PubMed
- Eur J Clin Pharmacol. 2013 Sep;69(9):1689-99 - PubMed
- Intern Med J. 2013 Aug;43(8):871-82 - PubMed
- Therapie. 2013 Jul-Aug;68(4):225-39 - PubMed
- Eur J Clin Pharmacol. 2014 Nov;70(11):1385-93 - PubMed
Background Clinicians prescribe high-cost medicines for rare diseases and nonapproved indications when conventional therapies have failed. Objective To examine the use of non-formulary high-cost medicines at an Australian public hospital. Methods Retrospective audit of individual patient use applications for nonformulary medicines costing more than $5000 AUD per year at a large tertiary referral hospital in Adelaide, South Australia over a 12-month study period from January 2015 to December 2015. Main outcome measures Total cost of non-formulary high-cost medicines, medication class, indications for use, level of supporting evidence and proposed monitoring outcomes. Results Eighty-seven individual patient use applications were examined. All except one were approved, at a total cost of $1,339,203 AUD. The most common drug classes were anti-CD20 (n = 33, 38%), combined antiretrovirals (n = 10, 11%) and TNF-alpha antagonists (n = 10, 11%). There were 56 indications for these medicines with the majority being inflammatory conditions (n = 52, 60%), followed by infections (n = 14, 16%) and malignancies (n = 14, 16%). Of the first-time individual patient use applications (n = 63), there were 25 applications (40%) that provided a case series as supporting evidence. Approximately half of new individual patient use applications (n = 32) proposed an objective monitoring outcome, but few (n = 13, 21%) contained sufficient information to allow a third party to determine efficacy of the medication. Conclusions Non-formulary high-cost medicines are being used for a broad range of indications based largely on low levels of evidence. Prospective definition of an adequate response to treatment and reporting of these outcomes is required to improve the evidence-base and to aid decision-making for subsequent treatment courses.
Keywords: Australia; Formulary; High-cost medicines; Hospital pharmacy.
Howe K, Bourke S, Sansom L. Howe K, et al. PLoS One. 2021 Dec 3;16(12):e0261022. doi: 10.1371/journal.pone.0261022. eCollection 2021. PLoS One. 2021. PMID: 34860857 Free PMC article. Review.
Sinha YK, Craig JC, Barclay PG, Miller H, Turner SC, Whitehouse JP, Brien JA. Sinha YK, et al. Med J Aust. 2014 May 19;200(9):541-5. doi: 10.5694/mja13.11138. Med J Aust. 2014. PMID: 24835719
Lambert R, Burgess N, Hillock N, Gailer J, Hissaria P, Merlin T, Pearson C, Reddi B, Ward M, Hill C. Lambert R, et al. Aust Health Rev. 2021 Mar;45(2):207-213. doi: 10.1071/AH20018. Aust Health Rev. 2021. PMID: 33762084
Helmons PJ, Kosterink JG, Daniels CE. Helmons PJ, et al. Am J Health Syst Pharm. 2014 Mar 1;71(5):407-15. doi: 10.2146/ajhp130219. Am J Health Syst Pharm. 2014. PMID: 24534596
Weekes LM, Day RO. Weekes LM, et al. Drug Saf. 1998 Mar;18(3):153-9. doi: 10.2165/00002018-199818030-00001. Drug Saf. 1998. PMID: 9530535 Review.
Nazar Z, Al Hail M, Al-Shaibi S, Hussain TA, Abdelkader NN, Pallivalapila A, Thomas B, Kassem WE, Hanssens Y, Mahfouz A, Ryan C, Stewart D. Nazar Z, et al. Int J Clin Pharm. 2023 Dec;45(6):1424-1433. doi: 10.1007/s11096-023-01616-7. Epub 2023 Jul 15. Int J Clin Pharm. 2023. PMID: 37454024 Free PMC article.
Balan S, Koo K, Muhamad Hamdan MD, Lee SV. Balan S, et al. Explor Res Clin Soc Pharm. 2022 Oct 12;8:100188. doi: 10.1016/j.rcsop.2022.100188. eCollection 2022 Dec. Explor Res Clin Soc Pharm. 2022. PMID: 36281358 Free PMC article.
Stafinski T, Glennie J, Young A, Menon D. Stafinski T, et al. Orphanet J Rare Dis. 2022 Jul 8;17(1):258. doi: 10.1186/s13023-022-02397-4. Orphanet J Rare Dis. 2022. PMID: 35804398 Free PMC article. Review.
Howe K, Bourke S, Sansom L. Howe K, et al. PLoS One. 2021 Dec 3;16(12):e0261022. doi: 10.1371/journal.pone.0261022. eCollection 2021. PLoS One. 2021. PMID: 34860857 Free PMC article. Review.